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METHODS ARTICLE
Sterilization of Lung Matrices by Supercritical
Carbon Dioxide
Jenna L. Balestrini, PhD,1,2 Angela Liu,1 Ashley L. Gard, MS,1 Janet Huie, PhD,3
Kelly M.S. Blatt, BS,3 Jonas Schwan, BS,1 Liping Zhao, MS,1 Tom J. Broekelmann, MS,4
Robert P. Mecham, PhD,4 Elise C. Wilcox, BS,1 and Laura E. Niklason, PhD, MD1,2
Lung engineering is a potential alternative to transplantation for patients with end-stage pulmonary failure. Two
challenges critical to the successful development of an engineered lung developed from a decellularized
scaffold include (i) the suppression of resident infectious bioburden in the lung matrix, and (ii) the ability to
sterilize decellularized tissues while preserving the essential biological and mechanical features intact. To date,
the majority of lungs are sterilized using high concentrations of peracetic acid (PAA) resulting in extracellular
matrix (ECM) depletion. These mechanically altered tissues have little to no storage potential. In this study, we
report a sterilizing technique using supercritical carbon dioxide (ScCO2) that can achieve a sterility assurance
level 10-6 in decellularized lung matrix. The effects of ScCO2 treatment on the histological, mechanical, and
biochemical properties of the sterile decellularized lung were evaluated and compared with those of freshly
decellularized lung matrix and with PAA-treated acellular lung. Exposure of the decellularized tissue to ScCO2
did not significantly alter tissue architecture, ECM content or organization (glycosaminoglycans, elastin, col-
lagen, and laminin), observations of cell engraftment, or mechanical integrity of the tissue. Furthermore, these
attributes of lung matrix did not change after 6 months in sterile buffer following sterilization with ScCO2,
indicating that ScCO2 produces a matrix that is stable during storage. The current study’s results indicate that
ScCO2 can be used to sterilize acellular lung tissue while simultaneously preserving key biological components
required for the function of the scaffold for regenerative medicine purposes.
Introduction
T issue engineering and regenerative medicine tech-nologies have made great strides in the past two de-
cades, including the development of decellularized scaffolds
for use in lung engineering.1–7 The creation of sterile, au-
tologous cell-sourced bioengineered lungs would enable the
construction of lungs that address patient-specific needs,
decrease the morbidity associated with immunosuppression,
and also address the worsening donor shortage of lungs for
transplantation. Two remaining challenges critical to the
clinical success of a donor-compatible organ transplant are
(i) the ability to suppress the growth of resident infectious
bacteria and other microorganisms, and (ii) the ability to
produce a scaffold that is stable over long-term storage.8,9
The availability of sterile lung scaffolds with significant
storage capacity would be a critical tool for one day con-
structing clinically viable, patient-specific lungs.
Unlike most organs, healthy lungs naturally have a sur-
prisingly diverse population of resident bacterial, fungal,
and viral organisms, including pathogens such as Haemo-
philus and Neisseria.10 The body’s resident macrophages
and immune mechanisms naturally keep these bioburden
levels low during health in vivo; however, unless ex vivo
microbial growth is controlled or stopped, donor lungs are
overgrown by bacteria and matrix damage ensues due to
bacterial collagenases and elastases.11 Even trace levels of
these native bacteria in implantable lungs would be con-
traindicated in lung recipients who are on immunosuppres-
sant therapy. Therefore, great care must be taken toward
ensuring the sterility of implantable materials.12
The industry standard for surgically implanted medical
devices to be deemed terminally sterile is a sterility assur-
ance level of 10-6 (SAL6). SAL6 is defined as having a
probability of one in a million that a given product is still
contaminated after sterilization treatment when starting with
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an initial bioburden of 106 colony-forming units (CFUs).13
Three commonly utilized methods of achieving SAL6 ste-
rility in soft tissues are g-irradiation, ethylene oxide (ETO)
sterilization, or perfusion with peracetic acid (PAA).14–16
Both g-irradiation and ETO sterilization are known to
produce important structural damage to tissues. Therefore,
these methods are not recommended for use in soft tissue
sterilization.14,17 PAA, a standard sterilizing agent, works
through oxidative disinfection and is highly effective
against bacteria, viruses, and spores.14,18,19 It has been
cleared for some applications by the Food and Drug Ad-
ministration,20 and recently has been used in the steriliza-
tion of lung tissue.21,22 However, reports on the impact of
PAA on extracellular matrix (ECM) and growth factor re-
tention in the acellular matrix are conflicting. While some
groups report mild architectural damage,8,23 others report
the depletion of critical growth factors, elution of soluble
ECM protein, and reduced mechanical integrity of decel-
lularized matrix.8,17,18 It is likely that these discrepancies
are due to differences in PAA concentrations (0.1–0.3%)
and tissue exposure times (20–160min). In addition to the
potential for ECM damage, PAA treatment alone may be
insufficient for matrix preservation in soft tissues such as
the lung.8,14 For example, decellularized lungs treated with
PAA are reported to have severely compromised tissue
architecture relative to freshly decellularized lungs after 6
months of storage.8
Supercritical carbon dioxide (ScCO2) has recently been
developed as a means to achieve SAL6 sterility in medical
devices, implantables, and allograft tissues.24–26 ScCO2 uti-
lizes extremely low levels of PAA (0.005–0.05%), and is
shown to achieve SAL6 with bacterial endospores.26 ScCO2
achieves sterilization through enhanced mass transfer of CO2
during the supercritical phase and disruption of the outer
membrane of bacterial, viral, or fungal bioburden.26 Further-
more, given that ScCO2 has a diffusion capacity that allows it
to penetrate matrix fibers, this process can sterilize at low
temperatures (35–39C) and remove unwanted compounds
such as blood or potentially residual DNA. Furthermore,
ScCO2 does not leave toxic residuals rendering it ideal as a
means to sterilize delicate ECM.27 Previous reports indicate
that soft tissues that undergo ScCO2 sterilization retained their
mechanical and molecular characteristics.25 To date, the use
of ScCO2 has not yet been investigated as a means to sterilize
or enable long-term storage capacity of decellularized lung
scaffolds. In the present study, we examined the effects of
ScCO2 sterilization on freshly decellularized rat lungs to a
standard application of PAA sterilization. We then assessed
the mechanical and biological composition of scaffolds, and
examined the cell seeding capacity of two different cell types
on ScCO2-treated matrix.
Materials and Methods
Organ harvest and decellularization
All animal experimental work was performed with approval
from the Yale University Institutional Animal Care and Use
Committee. All animal care complied with the Guide for the
Care and Use of Laboratory Animals. Briefly, 3-month-old
Sprague Dawley rats were pretreated intravenously with
500 U/kg heparin (Sigma-Aldrich) and euthanized.28 Im-
mediately after euthanasia, the abdomen was entered through
a transverse incision just below the costal margin. The dia-
phragm was punctured, and the rib cage was cut to reveal the
lungs. The lungs were then perfused through the right ventricle
with phosphate-buffered saline (PBS) containing 50U/mL
heparin and 1mg/mL sodium nitroprusside (Fluka). The heart,
lungs, and trachea were dissected free from the surrounding
muscles and connective tissue and removed en bloc. The
thymus was removed, and care was taken not to disrupt the
esophagus to minimize tissue damage and contamination
during dissection. Tracheal and pulmonary artery cannulae
were inserted and sutured into place to provide access for
perfusion and decellularization.
The lungs were decellularized as described previously.2
Briefly, the lungs were perfused with 0.0035% Triton X-100
in PBS, followed by Benzonase buffer and Benzonase nu-
clease. After the Benzonase treatment, a series of solutions
with increasing concentrations of sodium deoxycholate was
applied through the vasculature. The lungs were then rinsed
with 0.5% Triton X-100 and ethylenediaminetetraaceticacid
(EDTA) in PBS. Finally, an additional Benzonase step was
introduced at the end of the previously published method to
remove residual DNA. The reagent volumes were scaled to
tissue wet weight (average rat lung wet weight*2.5 g). For
all blood and debris clearance and decellularization steps,
the tissues were either perfused using a gravity feed at
22mm Hg pressure through the pulmonary artery or gently
flushed manually through the trachea. No antibiotics were
used during the decellularization process or before sterili-
zation treatments.
Sterilization procedures
Lung sterilization was completed at NovaSterilis in a
Nova2200 sterilizer. Decellularized lungs were stored in
Tyvek pouches, suspended in 100mL PBS, and sealed before
ScCO2 sterilization. To prevent tissue collapse, the airways of
the decellularized lungsweremanually filledwith 5–7mLPBS
and allowed a preconditioning time. To establish what amounts
of sterilization and preconditioning time were required for
SAL6 sterilization, the Nova2200 was run for a varied pre-
conditioning time (0.5–2h), and varied supercritical exposure
time (2–4 h). The chamber was filled at *1 psi/s, and the
system reached supercritical in*4–7min. During the sterili-
zation procedure, the Nova2200 was maintained at*1440psi
and 35C, and stirrer speed at *650 rpm. Following the 2-h
exposure to ScCO2, slow depressurization lasting 30–45min
was performed to maintain tissue temperature at or above
25C. Slow depressurization prevents freezing of the lung
tissue and fluid or expansion of gas in the lung resulting in
tissue destruction. For each sterilization run, the sterilizer was
loaded with 2mL of NovaKillTIM Gen2 (Novasterilis) additive
and samples before start of conditioning. Although PAA is a
component in the NovaKill Gen2 (13.5–18.5% PAA and 4.5–
6% hydrogen peroxide), the PAA level in the lung effluent
measured at an average of 0.018% (*10· less than typical
PAA concentration). For comparison, PAA lung tissues were
sterilized as established previously.8 Briefly, 30mL of 0.1%
PAA in 4% ethanol solution was perfused through the trachea
and the pulmonary artery of the decellularized lung. The lung
was then submerged in the solution for 2 h and rinsed with PBS
for 15min.8 All samples were stored in PBS at 4C without
antibiotics before examination.
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Validating SAL6 sterility
To develop a supercritical protocol that would produce a
terminally sterile tissue, SAL6 sterility was assessed in ac-
cordance with industrial sterilization validation guidelines.28
Briefly, biological indicator (BI) strips per sterilization
condition were inoculated with 106 Bacillus atrophaeus
spores (Mesa Labs) and placed under the variety of sterili-
zation conditions discussed above. BIs were either sus-
pended in PBS directly or wrapped in lung proxy materials
consisting of layers of semipermeable gauze (found to mimic
rat lung intratracheal inoculation results) and suspended in
PBS and tested at various run conditions. Samples were filter
recovered, incubated on a tryptic soy agar plate (not sup-
plemented with antibiotics) at 37C for 2 days and examined
for colony formation. Recovered BI strips were inoculated
into tryptic soy broth, incubated at 37C for 14 days, and
examined daily for bacterial growth.
Testing sterility in tissues
After each sterilization procedure was performed, using
decellularized lungs (ScCO2 or PAA), a subset of crushed
tissue samples and effluent (PBS from suspension and from
inside airways) were streaked on agar plates without selec-
tive inhibitor/antibiotics, as described previously.29 The
plates were incubated at 37C for 7 days, after which time
the number of bacterial colonies on each plate was recorded.
Native lung and freshly decellularized samples were used as
positive controls and formed bacterial colonies on the agar
plates.
Histology and immunostaining
Several portions of each lung (n = 3–5 areas, sampled
randomly) were isolated, fixed with 10% formalin for 4–6 h
at room temperature, stored overnight in 70% ethanol, em-
bedded in paraffin, and sectioned at 5 mm. Tissue slides were
stained for Hematoxylin and Eosin, Masson’s Trichrome
staining (Trichrome) for detecting collagen, Alcian Blue
(AB) at pH 2.5 for detecting glycosaminoglycans (GAGs),
and Verhoerff’s Van Geison (EVG) for detecting elastin.
Images were acquired using an Olympus BX/51 microscope
and associated Olympus DB70 digital camera.
For immunofluorescence, antigen retrieval was performed
in 1mM EDTA, 10mM Tris, and 0.05% Tween 20 buffer
for 20min at 75C and allowed to cool to room temperature
for 20min. After blocking sections with PBS containing
10% fetal bovine serum (FBS) and 0.2% Triton X-100 for
45min, primary antibodies were used against laminin (Ab-
cam ab74164; two drops, prediluted to 1:100) for 2 h at
room temperature. After washing slides with PBS, corre-
sponding secondary antibodies (AlexaFluor 555) were used
at 1:500 dilution for 45min. The slides were visualized
using a Leica DMI6000 B fluorescence microscope.
Tensile testing
Native, decellularized, PAA-treated, and ScCO2-treated
lung samples were analyzed using an Instron 5848. Ad-
ditionally, a subset of PAA-treated and ScCO2-treated
samples were stored for 6 months in PBS and analyzed.
Nominal 15· 2mm (length · width) strips were cut from
tissue samples. Care was taken to analyze tissue from the
distal region of the left rat lobe (so as not to include major
airways and pleura that could dominate mechanical analy-
sis). Tissue thickness of each sample was determined by a
series of measurements at four different points using a
digital micrometer (Mitutoyo). Specimens were glued to
1mm sections of sand paper at each end of the tissue slices,
and each end was affixed to grips. Tissues were then pre-
tared to 0.01N, cyclically preconditioned for three cycles to
15% strain, and pulled until failure at a strain rate of 1%/s.
The axial force was measured with a 10N load cell, and
elongation assessed by cross-head displacement. Tissues
were kept hydrated with PBS before and during the me-
chanical conditioning. Using tissue dimensions, engineering
stress and strain were calculated from force and distance




where, r is engineering stress, F= force, and A0= initial
area
e¼ lf  lo
lo
where e = engineering strain, lf= final length,
l0 = initial length.
The Young’s Modulus (E) for the tissue was determined
by dividing the engineering stress r, by the engineering
strain e, at low and high levels of deformation.
ECM analysis
Collagen was quantified with a colorimetric assay to detect
hydroxyproline as previously reported.30 Lung samples were
lyophilized and weighed, then incubated in papain (10U/mL;
25mg/mL) at 60C overnight (Sigma). Papain-digested sam-
ples analyzed for hydroxyproline content and collagen content
were calculated assuming a 1:12w/w ratio of hydroxyproline to
collagen. Sulfated GAGs (sGAGs) were quantified using the
Blyscan GAG Assay Kit (Biocolor). Lung samples were ly-
ophilized andweighed, then incubated in papain (25mg/mL) at
60C overnight (Sigma). Papain-digested samples (prepared as
described above for the collagen assay) were assayed according
to the manufacturer’s instructions. Absorption was measured
at a wavelength of 650 nm, and GAG content was quantified
using a standard curve. Elastin was measured by determining
the desmosine crosslinks as described previously.31 Briefly,
desmosine crosslinks were measured by first lyophilizing the
sample, hydrolyzing with 6N HCl for 48 h, and reconstituting
and filtering the tissue through a 0.45mm filter. The desmosine
levels were determined using a competitive enzyme-linked
immunosorbent assay.
Cell culture
Human A549 cells (a type II epithelial-like cell line) were
cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% FBS (Hyclone) and 1% penicillin and
100 mg/mL streptomycin (Corning). Rat microvascular lung
endothelial cells (RLMVECs; VEC Technologies) were
cultured in MCDB-131C (VEC Technologies).
The biocompatibility of ScCO2-treated acellular lungs after
6 months of storage was evaluated in vitro by seeding either
RLMVECs or A549 cells onto 1 cm2 decellularized tissue
slices. Briefly, 300mm thick acellular lung slices were seeded
at a concentration of 500,000 cells/slice and cultured for 3 days
as described previously.2 All cell-seeded slices were cultured
in standard cell culture conditions at 37C and 5% CO2.
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Statistics
Data are presented as the mean with standard error bars
representing the standard deviation. Data were analyzed by
Student’s t-test for significance and considered significantly
different if p < 0.05. All sterilization samples were compared
to freshly decellularized controls.
Results
Optimization of SAL6 sterility protocol using ScCO2
SAL6 sterilization using ScCO2 was evaluated across sev-
eral processing times and levels of PAA-containing additive
(Table 1). A minimum amount of 2 h of preconditioning time
and 1.5 h of ScCO2 exposure were required for the inactivation
of 106 Bacillus atrophaeus spores. To ensure confidence in
SAL6 sterility, all subsequent ScCO2 treatments consisted of
2 h of preconditioning time and 2 h of ScCO2 exposure. ScCO2
alone without the addition of PAA was not sufficient to inac-
tivate lung bioburden (data not shown).
Assessment of ScCO2 versus PAA sterility
To compare the effectiveness of PAA and ScCO2 steril-
ization techniques, crushed tissue and effluent from native,
freshly decellularized, and ScCO2- and PAA-sterilized lungs
were streaked onto LB agar plates and examined for bac-
terial colonies (n ‡ 4 for all groups). ScCO2- and PAA-
sterilized specimens were sampled 24 h after sterilization.
Bacterial colonies were detected in both native and decel-
lularized control tissues as early as 2 days after plating and
were present in varying numbers after 7 days (Fig. 1). CFUs
in freshly decellularized lungs (n = 5) ranged from 0 to 12
colonies, indicating variable presence of intrinsic bioburden
postdecellularization. There were no detectible colonies in
ScCO2-treated or PAA-treated decellularized rat lungs (n= 4
lungs per protocol) after 7 days (Fig. 1). After 6 months of
storage, there was no presence of bacterial colonies in
ScCO2- or PAA-treated lungs (data not shown). Therefore,
both sterilization methods are effective in removing intrinsic
bioburden in decellularized lungs.
Histological evaluation of the lung ECM post ScCO2
and PAA sterilization
Histological comparison was done between native, decel-
lularized, ScCO2-treated, and PAA-treated lungs (Fig. 2). The
decellularized tissue retained microstructure similar to native
tissue, with intact alveolar septae, vasculature, and airways
(Fig. 2A, B).2 In terms of general architecture maintenance,
tissues sterilized by either using PAA or ScCO2 did not
demonstrate major morphological differences relative to
freshly decellularized lungs, and the overall microarchitecture
of the lung was preserved (Fig. 2B–D). After 6 months of
storage, although the general architecture remained intact for
all sterilized tissue (Fig. 2E–H), the PAA-treated lungs dis-
played several areas that appeared damaged (indicated by ar-
rows) and the alveoli appeared distended (Fig. 2H). These data
indicate that even after several months of storage, ScCO2-
treated lungs retained structural integrity poststerilization.
Mechanical characterization of ScCO2-
and PAA-treated lungs
Results from mechanical testing of the native, decel-
lularized, PAA-sterilized and ScCO2-treated tissues are
shown in Figure 3 (n ‡ 5 for all groups). Figure 3A and C
show stress–strain curves of ScCO2 and PAA 24 h post-
sterilization treatment, and Figure 3B and D show ScCO2
and PAA 6 months poststerilization treatment. At deforma-
tions within typical tidal volumes (i.e., 1–10% strain),32–34
all sterilized tissue closely resembled freshly decellularized
lung and native lung (Fig. 3A–E). Specifically, at lower
strain levels (i.e., 5% strain), all freshly sterilized tissue had
Young’s moduli that did not differ significantly from freshly
decellularized lungs (Fig. 3E, p= 0.49, 0.96 respectively).
However, under large deformations (30%), tissues sterilized
with the ScCO2 (Fig. 3A–E) and PAA were significantly
stiffer than freshly decellularized lungs ( p= 0.047 and 0.046,
respectively). In contrast to these differences in moduli, there
were no statistical differences in freshly sterilized tissues
relative to freshly decellularized tissues in terms of failure
strain (24 h data, p= 0.07, 0.90, respectively Fig. 3E).
When examining tissues that were sterilized and stored
for 6 months in PBS, there was no significant change in
stiffness between ScCO2 samples after 24 h of storage and 6
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The NovaKill Gen2 additive amount was held constant, while
length of conditioning and ScCO2 exposure varied. All samples
inoculated with 106 Bacillus atrophaeus. A positive sample
represents growth on an agar plate.
ScCO2, supercritical carbon dioxide.
FIG. 1. Sterility assessment of decellularized lung matrix
sterilized with peracetic acid (PAA) and supercritical carbon
dioxide (ScCO2). Native, decellularized, ScCO2- and PAA-
treated rat lung tissue (n‡ 4) was crushed and streaked on
agar plates without antibiotic. ScCO2-treated and PAA-
treated tissues were tested 24 h poststerilization. The plates
were incubated at 37C for 7 days, after which the number
of bacterial colony-forming units (CFUs) on each plate was
recorded. Error bars represent – standard deviation.
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months of storage (27.3 vs. 21.5, p = 0.19, Fig. 3E). Tissues
sterilized with PAA consistently failed under lower defor-
mations ( p= 0.01, Fig. 3E) than freshly decellularized tis-
sues, whereas tissues sterilized with ScCO2 did not ( p= 0.21,
Fig. 3E). These data indicate that ScCO2 sterilization does
not negatively impact the mechanical integrity of acellular
lung tissue. Conversely, although PAA-treated samples ap-
pear unaltered mechanically 24 h after treatment, PAA-
treated samples have a higher moduli and lower failure strain
after 6 months of storage.
Quantitative biochemical analyses
of sterilized lung matrix
Collagen, elastin, and sGAG quantification of native,
freshly decellularized, ScCO2-sterilized, and PAA-sterilized
lungs are shown in Figure 4 (n ‡ 5). There is preservation of
total collagen content after ScCO2 and PAA sterilization
(Fig. 4A), as evidenced by a lack of statistical difference
between acellular and ScCO2- or PAA-sterilized tissue by
hydroxyproline assay (417, 449, and 433mg/mg dry tissue,
respectively; p = 0.19, 0.32). The amount of collagen in the
decellularized samples is presented as a fraction of dry
weight (both sterilized and non sterilized). It should be
noted that the increase of collagen content relative to tissue
mass is not a reflection of actual collagen production. Ra-
ther, this increase is an artificial concentration due to the
removal of cellular material.
Desmosine concentrations indicate that ScCO2-treated
lungs did not undergo any loss of elastin levels relative to
native tissues (3553 vs. 3320 ng/mg dry weight; p = 0.52),
whereas PAA-treated lungs did show a slight but significant
level of elastin loss (15% loss, p= 0.048) (Fig. 4B). As seen
previously, sGAG content was substantially depleted in
FIG. 2. Tissue characterization of decellularized lung matrix sterilized with PAA and ScCO2. Native (A), decellularized
(B), PAA- (C) and ScCO2 (D)-treated rat lung tissue stained with Hematoxylin and Eosin (H&E) shows maintenance of
tissue architecture in both ScCO2- and PAA-treated lung tissue immediately after sterilization. Insets (B–D) are at 400·.
H&E images of ScCO2 (E, F) and PAA (G, H)-treated tissue 6 months after treatment shows compromised tissue in PAA-
treated tissue (indicated by arrow) and not ScCO2-treated lung tissue after 6 months of storage. Scale bar = 50 mm applies to
all panels. Color images available online at www.liebertpub.com/tec
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FIG. 3. Mechanical prop-
erties of sterilized, decel-
lularized lung tissue.
Representative stress–strain
curves of native, freshly de-
cellularized and acellular rat
lung tissue sterilized through
(A, B) ScCO2 and (C, D)
PAA, tested immediately
after treatment and after 6
months of storage. Stress–
strain curves of native and
decellularized lung tissue
(n ‡ 5 for all groups). (E)
Biochemical and mechanical
composition of tissues in na-
tive and decellularized con-
ditions. Error bars show
mean – standard deviation,
and ‘‘*’’ indicates signifi-
cance from decellularized
matrix at p £ 0.05. Color
images available online at
www.liebertpub.com/tec
FIG. 4. Quantifying impact of sterilization on extracel-
lular matrix retention. Quantification of (A) collagen, (B)
elastin, and (C) sulfated GAGs (sGAGs) in native (n‡ 5),
decellularized tissue (n= 15), PAA-treated and ScCO2-
treated tissue immediately after processing. Data demonstrate
retention of collagen, elastin, and sulfated GAGs in ScCO2-
treated tissue and elastin loss in PAA-treated tissue. ‘‘*’’
Indicates significance from decellularized matrix at p£ 0.05.
Error bars show mean– standard deviation.
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decellularized lungs relative to native tissue.2 (Fig. 4C). The
impact of sterilization (ScCO2 or PAA), however, had a
negligible effect on the sGAG content of lung tissue (4.0,
5.1, and 4.3 mg/mg dry weight, respectively; p = 0.15, 0.52).
These data indicate that ScCO2 sterilization does not ad-
versely impact collagen, elastin, or sGAG content in acel-
lular lungs. In addition, PAA sterilization does negatively
impact elastin content in acellular lungs.
ECM retention in ScCO2-sterilized lungs
To visually examine ECM constructs in native, decel-
lularized, and ScCO2-treated lungs, elastin fibers (EVG,
Fig. 5A–C), collagen type I (Trichrome, Fig. 5D–F), GAGs
(AB, Fig. 5G–I), and laminin (Fig. 5J–L) were imaged.
ScCO2 samples were imaged 24 h after sterilization. As seen
previously, the decellularized tissue retained the majority
of elastin (black fibers, Fig. 5B, C), collagen (blue fibers,
Fig. 5E, F), laminin (shown in red, Fig. 5K, L), and mi-
crostructure after decellularization. It should be noted that
EVG stain (Fig. 5A–C) simultaneously stains cells and
elastin, and that the difference in appearance between native
and decellularized tissue is largely due to the decellular-
ization process (Fig. 5A, B). These data indicate that ScCO2
sterilization does not adversely impact type I collagen,
elastin, sGAG, or laminin architecture in acellular lungs.
Recellularization and slice culture
To determine if the resulting sterilized acellular tissue is
adequate for cell seeding after long-term storage, and also to
investigate the in vitro potential of the rat scaffold for re-
cellularization with relevant cell types (endothelial and ep-
ithelial cells), sections of lungs were reseeded with A549
(Fig. 6A) and RLMVEC cells (Fig. 6B). Acellular, ScCO2-
sterilized lung tissues enabled homogeneous epithelial and
endothelial cell engraftment. A549 cells attached to the
matrices, elongated, lined the small and large airways, and
remained viable for 3 days. RLMVECs also engrafted well,
spread along the tissue, and remained viable for 3 days.
Therefore, the resulting sterilized tissue is capable of pro-
viding a suitable scaffold for cell growth even after several
months of storage.
Discussion
Producing a SAL6 sterile, biocompatible tissue scaffold
for use in transplant therapies provides a very difficult set of
challenges. The biomechanical and biological properties of
the tissue can be adversely affected during terminal sterili-
zation. For example, gamma radiation of acellular lung
tissue causes significant structural damage and irreversible
degradation of ECM.8 Our results indicate that sterilization
of ScCO2 overcomes these limitations commonly associated
with other sterilization methods while effectively eliminat-
ing bioburden. Specifically, ScCO2-sterilized tissue retains
key ECM constituents (collagen, elastin, sGAGs) and me-
chanical characteristics (failure properties and stiffness)
immediately after treatment, and retains these characteris-
tics after 6 months of storage. Furthermore, this sterilized
acellular tissue is hospitable to epithelial and endothelial
engraftment even after 6-month storage of the tissue. To the
best of our knowledge, this is the first report of a SAL6
method that preserves biological and mechanical properties
in decellularized lung matrix.
To date, the majority of decellularization protocols for lung
decellularization and lung engineering suppress resident bio-
burden using a combination of antibiotics.1,5,16,22,35–37 With
recent improvements in decellularization that utilize gentler
detergents and milder conditions to retain ECM compo-
nents,2,4,38 antibiotics are increasingly ineffective in removing
the pre-existing bioburden (Fig. 1). These antibiotics also have
FIG. 5. Characterization of sterilized acellular lung ma-
trix. (A–C) Representative micrographs of native, decel-
lularized, and ScCO2-treated lung tissue stained with
Verhoeff’s Van Gieson (EVG) to examine elastin, (D–F)
Masson’s Trichrome to examine tissue architecture and
collagen preservation, (G–I) and Alcian Blue to observe
GAG presence. The EVG, Trichrome, and Alcian Blue stain
show maintenance of general tissue architecture, collagen
type I and elastin fibers, and total GAGs content throughout
the tissue after treatment with ScCO2. Representative fluo-
rescence micrographs of (J) native, (K) decellularized, and
(L) ScCO2-treated lung tissue show maintenance of laminin
content throughout the tissue after treatment with ScCO2.
Scale bar= 100mm applies to all panels. Color images
available online at www.liebertpub.com/tec
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no effect on viral contaminants or multidrug-resistant bacterial
growth, issues that become critical when advancing to human
lung sources.12,14,39,40 Finally, if residual antibiotics remain in
the scaffold postdecellularization, ultimate risk to patients who
are allergic to these antibiotics becomes a potential issue.23
Therefore, developing an effective sterilization method inde-
pendent of antibiotic use is an important advance for the field.
Currently, there are no published sterilization methods
capable of attaining SAL6 sterility in acellular lungs without
significant damage to the tissue. As with any implantable
medical device utilized in the healthcare industry, tissue-
engineered products must reach a sterility level of SAL6 for a
claim of sterility to be made.41 To establish that a system has
a sterility level of SAL6, the bacterial species used in sterility
validations must exhibit resistance to inactivation. Spore-
forming bacteria, such as Bacillus atrophaeus are commonly
used for this purpose because of their resistance to traditional
sterilization processes.42,43 Our results showed that traditional
sterilization methods (i.e., 0.1% PAA treatment) of acellular
lung did result in a complete reduction of bioburden; how-
ever, this treatment also resulted in a significant loss of elastin
content and compromised tissue architecture (Figs. 2F and
4B). Although a minimal amount of PAA is required for
ScCO2 sterilization to be effective, the concentration was
only 10% of that traditionally used for PAA sterilization.
When examining ECM content and organization through
biochemical quantification or histological staining, ScCO2 did
not result in the significant removal of collagen, elastin, or
sGAGs (Fig. 4). Furthermore, the tissue architecture closely
resembled freshly decellularized tissue with respect to col-
lagen, elastin, GAG, and laminin organization (Fig. 5). The
sterilization procedure did produce a stiffer tissue, but this
increase in stiffness was only significant in nonphysiological
levels of stretch. Although the reason for the increase in
stiffness is unclear, it is possibly due to crosslinking of matrix
under high pressures during sterilization. It is possible that if
this crosslinking exists, it could be providing protection from
hydrolysis associated with long-term storage and contributing
to the integrity of ScCO2-treated tissue over time.
We also investigated the sterilized tissues after 6 months
in storage with PBS (without antibiotics) as a means to
ensure the retention of these characteristics and examine the
preservation of scaffolds. There were no significant differ-
ences between the mechanical properties of the freshly
ScCO2-sterilized tissue and tissue that had been stored for 6
months in terms of stiffness or failure properties (Fig. 3A, B,
and E). Interestingly, although PAA-treated tissues closely
resembled decellularized tissues immediately after sterili-
zation (Fig. 3C, E), after 6 months of storage the samples
were brittle and could withstand significantly less stress
before failing as compared to freshly PAA-treated tissue.
The observed decrease in mechanical integrity of stored
PAA-treated tissues is likely due, in part, to depletion of
elastin and soluble matrix components and potentially due to
dehydration associated with ethanol treatment.
Elastin loss is often associated with diseases such as em-
physema.44,45 Furthermore, in addition to providing elastic
recoil in the lung, elastin and elastin degradation products are
able to influence cell function and promote cellular responses
such as chemotaxis, proliferation, and cell adhesion.46,47 Elastin
is also essential in lung development and could impair re-
cellularization of the tissue.48,49 Finally, elastin is not a protein
that is generally regenerated in the adult lung49 and, therefore,
the depletion of elastin, unlike other ECM proteins, would likely
be irreversible. Therefore, it is essential that the elastin content of
the lung remain preserved during the sterilization process.
In this work, we demonstrated that ScCO2 did not cause
any major structural and biological degradation of acellular
lung matrix, and produced a sterile lung scaffold that can be
stored long term. The stored, sterile tissues were also well
suited for cell adhesion and survival. We showed that ScCO2
surpassed traditional PAA sterilization in the capacity for
retention of key biological and mechanical features. There-
fore, use of ScCO2 sterilization may be a powerful tool for
whole organ decellularization technologies.
FIG. 6. Recellularization of ScCO2-treated rat lung tissue
slices. Representative H&E stained tissue slices seeded with
(A) human epithelial (A549) and (B) rat endothelial (rat
microvascular lung endothelial cells [RLMVECs]) cells.
Cells were seeded at a concentration of 500,000 cells/slice
and cultured for 3 days. Tissue was ScCO2 treated and
stored in phosphate-buffered saline for 6 months before
seeding. All cells homogenously engrafted in the tissue
demonstrating the capacity for recellularization of sterilized
acellular matrix. Scale bar = 50mm. Color images available
online at www.liebertpub.com/tec
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Conclusions
The use of ScCO2 presents a novel, user-friendly process
to sterilize acellular tissue for use in tissue and organ en-
gineering. The entire protocol can be accomplished in*3 h,
and yields a sterile acellular matrix that retains critical
structural, adhesive, and supportive proteins such as colla-
gen, elastin, laminin, and polysaccharides such as sGAGs.
Furthermore, after 6 months of storage, ScCO2-treated tis-
sues maintain mechanical properties and cell seeding ca-
pacity. Taken together, these results suggest that the
proposed sterilization protocol provides a time-efficient and
reproducible method to create sterile scaffolds for use in
tissue engineering.
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